- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
TOM1 antibody detects Target of Myb protein 1, encoded by the TOM1 gene on chromosome 22q13.1. TOM1 antibody is widely applied in the study of intracellular trafficking and endosomal sorting. TOM1 belongs to a conserved protein family involved in endosomal trafficking, autophagy, and receptor signaling regulation. It was originally identified as a protein interacting with the transcription factor Myb, but subsequent research has shown its main functions lie in vesicular transport and signaling integration at early endosomes. Expression is observed in a wide range of tissues, including brain, lung, liver, and immune cells, where TOM1 contributes to receptor downregulation and lysosomal targeting.
Structurally, TOM1 contains an N-terminal VHS (Vps27, Hrs, STAM) domain that binds phosphatidylinositol-3-phosphate (PI3P) and ubiquitin-tagged cargo. It also includes a GAT (GGA and TOM1) domain that mediates interactions with clathrin and other trafficking proteins. The C-terminal region interacts with Tollip (Toll-interacting protein), linking TOM1 to endosomal sorting of receptors. These modular domains position TOM1 as a scaffold that integrates lipid binding, cargo recognition, and adaptor protein recruitment for endosomal trafficking.
Functionally, TOM1 regulates receptor endocytosis and degradation. By binding ubiquitinated cargo and interacting with clathrin, TOM1 helps direct activated receptor tyrosine kinases, Toll-like receptors, and growth factor receptors toward lysosomal degradation. TOM1 also contributes to autophagy by interacting with proteins such as Myosin VI, directing cargo toward autophagosomes. Knockdown of TOM1 disrupts endosomal sorting, resulting in receptor accumulation and dysregulated signaling. Researchers employ TOM1 antibody to examine its roles in endocytosis, receptor turnover, and autophagic flux.
Clinically, altered TOM1 expression has been associated with inflammatory disease and cancer. Overexpression of TOM1 enhances degradation of activated receptors, reducing signaling intensity, while reduced expression may prolong receptor activation. Dysregulation of TOM1 has been implicated in chronic inflammatory states, where defective receptor turnover contributes to hyperactive immune responses. In oncology, TOM1 overexpression has been reported in some tumor types, potentially linking it to altered growth factor signaling. Further studies continue to explore its clinical significance.
Experimentally, TOM1 antibody is used in western blotting to detect the ~54 kDa protein, in immunofluorescence to localize it to endosomes, and in immunohistochemistry to evaluate tissue expression. Co-immunoprecipitation with TOM1 antibody helps identify binding partners such as Tollip, clathrin, and Myosin VI. NSJ Bioreagents provides TOM1 antibody for use in studies of endosomal trafficking, receptor regulation, and autophagy.
Optimal dilution of the TOM1 antibody should be determined by the researcher.
E.coli-derived human TOM1 recombinant protein (Position: R84-K480) was used as the immunogen for the TOM1 antibody.
After reconstitution, the TOM1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.